We provide you with 20 years of free, institutional-grade data for KYMR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KYMR. Explore the full financial landscape of KYMR stock.
| Reported Date | CIK | Ticker | Type |
|---|
Kymera Therapeutics, Inc(NASDAQ:KYMR) 
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase...
Website: http://www.kymeratx.com
Founded: 2016
Full Time Employees: 64
CEO: Nello Mainolfi
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about KYMR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.